Alpelisib: tested in a combination
44 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2Report a problem
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingNCT06545682Phase 1Report a problem
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingNCT05983159Phase 2Report a problem
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2Report a problem
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)RecruitingNCT05660083Phase 2Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2Report a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingNCT04817956Phase 2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerCompletedNCT05101564Phase 2Results postedReport a problem
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedNCT04729387Phase 3Results postedReport a problem
- Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsTerminatedNCT04216472Phase 2Results postedReport a problem
- Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results postedReport a problem
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsCompletedNCT03056755Phase 2Results postedReport a problem
- A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results postedReport a problem
- Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal WomenCompletedNCT01923168Phase 2Results postedReport a problem
- Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal CancerCompletedNCT01719380Phase 2Results postedReport a problem
- A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid TumorsTerminatedNCT01708161Phase 1/2Results postedReport a problem
- A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT01602315Phase 1/2Results postedReport a problem
- Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell CarcinomaWithdrawnNCT05472220Phase 1Report a problem
- SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)Active, not recruitingNCT05392608Phase 2Report a problem
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2Report a problem
- Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy VolunteersCompletedNCT05195892Phase 1Report a problem
- A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingNCT05154487Phase 2Report a problem
- Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingNCT05143229Phase 1Report a problem
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3Report a problem
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedNCT04997902Phase 1/2Report a problem
- Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC PatientsActive, not recruitingNCT04753203Phase 1/2Report a problem
- Alpelisib and Paclitaxel in PIK3CA-altered Gastric CancerStatus unknownNCT04526470Phase 1/2Report a problem
- Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasActive, not recruitingNCT03631953Phase 1Report a problem
- Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2Report a problem
- Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast CancerCompletedNCT03207529Phase 1Report a problem
- Trial of AEB071 in Combination With BYL719 in Patients With MelanomaCompletedNCT02273219Phase 1Report a problem
- Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerCompletedNCT02167854Phase 1Report a problem
- Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT02144038Phase 1Report a problem
- Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerCompletedNCT02088684Phase 1Report a problem
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT02058381Phase 1Report a problem
- Phase 1b Trial of BGJ398/BYL719 in Solid TumorsCompletedNCT01928459Phase 1Report a problem
- Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerActive, not recruitingNCT01872260Phase 1/2Report a problem
- Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)CompletedNCT01822613Phase 1Report a problem
- BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT01791478Phase 1Report a problem
- A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST PatientsCompletedNCT01735968Phase 1Report a problem
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1Report a problem
- PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric CancerCompletedNCT01613950Phase 1Report a problem
- A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid TumorsCompletedNCT01449058Phase 1Report a problem